As the world deals with a pandemic, there remains another global challenge that cannot be ignored.
Use of broad-spectrum antibiotics may be justified as we are trying to treat a novel disease condition, which in turn could lead to an increase in antimicrobial resistance.
We can decrease morbidity, mortality, and health care costs by controlling antimicrobial resistance
but it requires antimicrobial stewardship.
Major components of effective and timely antimicrobial stewardship are diagnostic stewardship, infection prevention and control, and integration of COVID-19 specific flags into electronic health records
all of which may be integrated into current strategies of COVID-19 mitigation and management.
Going through the influenza season of 2020, implementation of antimicrobial stewardship education efforts in the United States can help us contend with influenza in addition to COVID-19.
Additional solutions include the development of vaccines, alternative therapies such as antibodies, and advanced diagnostics using advances in genomics and computer science.
AMS: antimicrobial stewardship
It is time to seriously think of AMS and revisit institutional policies as we head into COVID-19.